Head-to-head evidence
RTN-001 vs sildenafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: PDE5 · full Hypertension pipeline
RTN-001
Developed by Retension Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07142356 (registry estimate)
sildenafil · Revatio
Marketed by Viatris and partners
NCT00644605 · Phase 3 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: May 2027 · NCT07647003 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: RTN-001's landscape · sildenafil's landscape